Citigroup Cuts Alnylam Pharmaceuticals Price Target to $320 From $340
Citigroup cut its price target on Alnylam Pharmaceuticals to $320 per share from $340 and maintained its Buy rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.